Justin Bader

<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

Miao Zhao, Alexander J. Lepak, Brian VanScoy et al. · Antimicrobial Agents and Chemotherapy · 2018 · 66 citations · Full text

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Justin Bader, Elizabeth A. Lakota, Shawn D. Flanagan et al. · Antimicrobial Agents and Chemotherapy · 2018 · 44 citations · Full text

Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations

Joseph A. Paladino, David M. Jacobs, Ryan K. Shields et al. · International Journal of Antimicrobial Agents · 2014 · 39 citations

Antimicrobial Susceptibility, Antibiotics, Glycopeptide Failure +7

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

Elizabeth A. Lakota, Justin Bader, Voon Ong et al. · Antimicrobial Agents and Chemotherapy · 2017 · 37 citations · Full text

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

Sujata M. Bhavnani, Li Zhang, Jeffrey Hammel et al. · Journal of Antimicrobial Chemotherapy · 2019 · 25 citations · Full text